Your browser doesn't support javascript.
loading
Adenosine Receptor Subtypes and Cardioprotection.
Lee, Jang Eun; Wilcox, Karen; Jacobson, Kenneth A; Dichter, Marc; Liang, Bruce T.
Afiliação
  • Lee JE; Department of Medicine, Cardiovascular Division, Philadelphia, Pennsylvania.
  • Wilcox K; Mahoney Institute for Neurological Sciences, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania.
  • Jacobson KA; Laboratory of Bioorganic Chemistry, National Institutes of Health, Bethesda, Maryland.
  • Dichter M; Mahoney Institute for Neurological Sciences, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania.
  • Liang BT; Department of Medicine, Cardiovascular Division, Philadelphia, Pennsylvania.
Drug Dev Res ; 45(3-4): 394-401, 1998.
Article em En | MEDLINE | ID: mdl-38234711
ABSTRACT
Brief ischemia prior to a sustained period of ischemia reduces myocardial infarct size, a phenomenon known as preconditioning. A cardiac ventricular myocyte model has been developed to investigate the role and signaling mechanism of adenosine receptor subtypes in cardiac preconditioning. A 5-min exposure of cardiac myocytes to simulated ischemia, termed preconditioning ischemia, prior to a subsequent 90-min period of ischemia protected them against injury incurred during the 90-min ischemia. Preconditioning ischemia preserved ATP content, reduced percentage of cells killed, and decreased release of creatine kinase into the medium. Activation of the adenosine A1 receptor with CCPA or the A3 receptor with IB-MECA can replace preconditioning ischemia and mimic the protective effect of preconditioning ischemia. Blockade of the A1 receptor with its selective antagonist DPCPX or of the A3 receptor with the A3 selective antagonist MRS1191 during the preconditioning ischemia resulted in only a partial attenuation of the subsequent protection. Incubation with both DPCPX and MRS1191 or with the nonselective antagonist 8-SPT during the preconditioning ischemia completely abolished the protective effect of preconditioning ischemia. The KATP channel opener pinacidil caused a large activation of the KATP channel current and was able to precondition the myocyte. The KATP channel antagonist glibenclamide blocked the cardioprotective effect of preconditioning ischemia when it was included during myocyte exposure to the preconditioning ischemia, indicating that KATP channel is a requisite effector in mediating preconditioning. A receptor-mediated stimulation of phospholipase C or phospholipase D, with consequent activation of protein kinase C and KATP channel, appears to be the signaling mechanism linking adenosine A1 and A3 receptors to the induction of preconditioning. A model of how ischemic preconditioning is triggered and mediated is proposed. Evidence is accumulating to support its validity.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 1998 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 1998 Tipo de documento: Article